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Rapport de synthèse 
Enjeux et contexte 
La recherche de cette dernière décennie sur les acides gras n-3 PUFA contenus dans l'huile de 
poisson a montré que ceux-ci, et particulièrement l'EPA et le DHA, avaient des propriétés anti-
inflammatoires et anti arythmiques puissantes, potentiellement utiles chez les septiques et 
«cardiaques». Les mécanismes sous-jacents sont nombreux, incluant l'incorporation des acides 
gras dans les membranes de phopholipides, la réduction de la production de médiateurs pro-
inflammatoires (prostaglandines, leukotrienes, thromboxane), l'augmentation de la production de 
résolvines et protectines dérivées du DHA, et la régulation de voies de signalisation cellulaire. 
Cependant, les doses de n-3 PUFA utilisées dans les études cliniques et chez le sujet sain avant 
le travail de Yann-Karim Pittet étaient nettement supérieures aux doses nutritionnelles de l'ordre 
de 5-8 g/j par voie orale ou 1 g/kg par voie intraveineuse. De plus, la voie entérale avait la 
réputation de nécessiter plusieurs jours à semaines de traitement avant d'aboutir à une 
incorporation d'acides gras membranaire suffisante pour avoir un impact clinique; quant au temps 
minimal requis pour obtenir cet effet par voie IV, il était inconnu. 
Depuis, le développement d'émulsions lipidiques intraveineuses destinées à la nutrition 
parentérale a permis d'imaginer l'administration de prétraitements IV rapides. Pour les étudier, 
notre laboratoire a développé un modèle d'endotoxine (LPS d'E.Coli) qui mime les réponses 
physiologique, endocrinienne et biologique du sepsis chez le sujet sain, utilisant des doses de 2 
ng/kg IV. Les réponses sont totalement réversibles en 8 heures. 
Dans le but de réduire à la fois la dose de lipides et le temps de perfusion, ce travail a étudié 
l'influence de 3 doses dégressives de n-3 PUFA sur les réponses à l'endotoxine, et sur 
l'incorporation membranaire de ces acides gras. 
Méthodes 
Etude prospective chez 3 groupes consécutifs de sujets sains soumis à un challenge 
d'endotoxine. 
Intervention: perfusions d'huile de poisson (0.5 et 0.2 g/kg de n-3 PUFA, Omegaven® 10%) ou 
placebo, administrées en 3 heures ou en 1 heure, soit le jour avant ou le jour-même du test 
d'endotoxine. 
Mesures: variables physiologiques (T°, fc, tension artérielle, calorimétrie indirecte) 
Laboratoire - prises de sang à TO, 60, 120 et 360 min après l'injection de LPS: TNF-a, hs-CRP, 
hormones de stress, composition en acides gras des membranes plaquettaires. 
Statistiques 
Les résultats ont été rapportés en moyennes et écarts types. Des aires sous la courbe (AUC) ont 
été calculées avec la méthode des parallélépipèdes pour toutes les variables déterminées de 
manière répétée. L'effet du temps a été exploré par des two-way ANOVA pour mesures répétées. 
Les comparaisons post-hoc ont été réalisées avec des tests de Dunnett's ou de Scheffe. Les 
modifications de composition membranaires ainsi que les AUC ont été analysées par des tests 
non-paramétriques (Kruskal-Wallis ). 
Résultats 
Après LPS, la température, les concentrations d'ACTH et TNF-a ont augmenté dans les 3 
groupes. Ces réponse ont été significativement atténuées (p<0.0001) par l'huile de poisson 
comparé à ce que nous avions observé dans le groupe contrôle de Pluess et al (ICM 2007). Les 
concentrations les plus faibles d'ACTH, de TNF-a, et les AUC les plus basses des températures, 
ont été observées après une dose unique de 0.2 g/kg de n-3 PUFA administrée 1 heure avant le 
LPS. Par contre, l'incorporation membranaire d'EPA est dose-dépendante. 
Conclusions 
Sachant que la réponse à l'endotoxine est reproductible, cette étude montre que 3 doses 
différentes d'huile de poisson atténuent de manière différente cette réponse. La perfusion de 0.2 
g/kg administrée juste avant l'endotoxine s'est avérée la plus efficace à atténuer la réponse 
fébrile, les cytokines et les hormones de stress, suggérant une capture de l'endotoxine par 
l'émulsion lipidique qui se surajoute aux effets systémiques et membranaires. 
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Blunting the response to endotoxin 
in healthy subjects: effects of various 
doses of intravenous fish oil 
Abstract Objective: To test the 
dose response effect of infused fish 
oil (FO) rich in n-3 PUFAs on the 
inflammatory response to endotoxin 
(LPS) and on membrane incorpora-
tion of fatty acids in healthy subjects. 
Design: Prospective, sequential 
investigation comparing three differ-
ent FO doses. Subjects: Three 
groups of male subjects aged 
26.8 ± 3.2 years (BMI 22.5 ± 2.1). 
Intervention: One of three FO doses 
(Omegaven®10%) as a slow infusion 
before LPS: 0.5 g/kg 1 day before 
LPS, 0.2 g/kg 1 day before, or 
0.2 g/kg 2 h before. Measurements 
and results: Temperature, hemody-
namic variables, indirect calorimetry 
and blood samples (TNF-o:, stress 
hormones) were collected. After LPS 
temperature, ACTH and TNF-o: con-
centrations increased in the three 
groups: the responses were 
significantly blunted (p < 0.0001) 
compared with the control group of 
the Pluess et al. trial. Cortisol was 
unchanged. Lowest plasma ACTH, 
TNF-o: and temperature AUC values 
were observed after a single 0.2 g/kg 
dose of FO. EPA incorporation into 
platelet membranes was dose-depen-
dent. Conclusions: Having 
previously shown that the response to 
LPS was reproducible, this study 
shows that three FO doses blunted it 
to various degrees, The 0.2 g/kg per-
fusion immediately before LPS was 
the most efficient in blunting the 
responses, suggesting LPS capture in 
addition to the systemic and mem-
brane effects. 
Keywords Inflammation · Sepsis · 
PUFA · Downregulation 
Introduction eicosanoids and cytokines, adhesion molecules, as well as 
genes involved in inflammation, by modifying phospho-
The interest in polyunsaturated fatty acid (PUFA) sup- lipid membrane composition in the immune cells [l, 2]; In 
plementation has generated a large body of research addition, the n-3 PUFAs modulate key metabolic path-
during the last decade. Among PUFA, the n-3 PUFAs ways, platelet fonctions and the excitability of 
eicosapentaenoic acid (C20:5n-3, EPA) and docosahexa- cardiomyocytes. Oral FO has been shown to exert bene-
enoic acid (C22:6n-3, DHA), produced by plankton and ficial effects in patients with inflammatory diseases and 
incorporated by fish, are the most biologically active. Fish elevated cardiovascular risk [1]. While oral administra-
oil (FO) consumption increases the proportion of EPA tion requires time to achieve these beneficial effects [3], 
and DHA in the cell membrane phospholipids, particu- data in volunteers show that the intravenous administra-
larly in the monocytes and inflammatory cells. They tion achieves biological effects in a few hours [4]. The 
modulate the inflammatory processes by various mecha- development of intravenous lipid emulsions containing 
nisms, including downregulation of proinflammatory FO enables exploring such properties in acute conditions. 
Published online: 21 October 2009 
In a previous trial we showed that the intravenous 
administration of two doses of 0.5 g/kg of FO in healthy 
subjects resulted in a rapid incorporation of EPA and 
DRA into the platelet membrane phospholipids [4]. This 
was associated with a significant downregulation of the 
neuroendocrine responses to endotoxin (LPS), as well as 
of some components of the inftammatory response. In the 
previous study, the 0.5 g/kg FO dose required a prolonged 
infusion time (6 h). We hypothesized that smaller doses 
of FO could exe1t similar effects with the advantage of a 
reduction of infusion time and of total fat dose. Indeed in 
acute medical settings, the two latter characteristics might 
be an advantage when a rapid effect is required or the fat 
tolerance is low (e.g., acute coronary conditions). 
The present study aimed at comparing the effect of 
various doses of intravenous FO in healthy subjects by 
consecutive trials with three gradually decreasing FO 
doses on membrane incorporation of n-3 PUFAs, as well 
as on the physiological response to LPS. 
Subjects and methods 
After approval by the ethics committee of Lausanne's 
University School of Medicine, and with written informed 
consent, healthy male subjects were enrolled in three 
consecutive trials. A complete history (including a ques-
tionnaire on the frequency of fish intake) and physical 
examination were performed before the study; a 12-lead 
electrocardiogram was recorded. The inclusion criteria 
were the following: age 18-35 years, being in good health 
and taking no medications. Exclusion criteria were 
smoking > 10 cigarettes/day, alcohol consumption > 1 
glass wine or 1 beer/day, and a sea fish intake > twice 
weekly, or EPA/DHA supplementation. 
Experimental design and treatment 
Three consecutive studies were carried out testing various 
regimens of intravenous FO in subjects submitted to the 
same endotoxin challenge, using decreasing doses. The 
trial used the same design as our previous randomized trial 
comparing two doses of 0.5 g/kg FO versus placebo [4]: 
o Day -1, 0.5 g/kg group: one 0.5 g/kg infusion of FO in 
6 h, 24 h before the investigation day (n = 8). 
o Day -1, 0.2 g/kg group: one 0.2 g/kg infusion of FO in 
3 h, 24 h before the investigation day (n = 6). 
o Dày 0, 0.2 g/kg group: one 0.2 g/kg infusion of FO in 
3 h, 2 h before the investigation (n = 7). 
A purified FO solution was used in all groups 
(Omegaven®10%, provided by Fresenius Kabi AG, Bad 
Homburg, Germany): 100 ml contain 10 g of FO, 
providing 1.25-2.82 g of EPA; 1.44-3.09 g of DHA and 
15-29.6 mg of D,L-a-tocopherol as antioxidant. 
Infusion protocol 
On the investigation day, subjects came at 8 a.m. to the 
metabolic laboratory after an overnight fast. They were 
requested to void, and the urine was discarded. Thereaf-
ter, they remained recumbent for the next 8 h. A venous 
catheter was inserted into a vein of the left forearm for 
LPS injection and labeled glucose infusion, and another 
catheter was placed into a wrist vein of the right forearm 
for blood sampling to avoid contamination of blood 
samples by the infusion. The right hand was kept in a 
thermo-stabilized box, heated at 56°C to achieve partial 
arterialization of verrous blood. 
Intervention 
A dose of 2 ng/kg of endotoxin from E. Coli (USP, 
Rockville, MD, batch no. 2, as a 200 ng/ml solution in 
NaCl 0.9%) was given as an intravenous bolus at time TO 
(injection time: 1 min). 
Vital fonctions, including heart rate, respiratory rate, 
rectal temperature (Hellige, Servomed), non-invasive 
arterial blood pressure (Critikon, Dinamap), cardiac out-
put [thoracic bioimpedance (NCCOM3 cardiodynamic 
monitor, BoMed, Irvine, CA] and oxygen saturation 
(Ohmeda, Biox 3740 Pulse oximeter), were monitored. 
Subjective symptoms such as muscle pain and headache, 
nausea and vomiting were recorded. 
Blood collection and analysis 
Blood was drawn twice before the endotoxin challenge: 
before the first infusion of FO and before the challenge. 
Blood was drawn in tubes containing EDTA and plasma 
immediately separated by low speed centrifugation (228 
GIGA for 10 min at 4°C). The plasma supernatant was 
further centrifuged for 20 min at 1428 GIGA. Platelets 
were then "washed" twice and centrifuged in a TRIS 
solution. Thereafter, storage was done in formol at -80°C 
until analysis. For fatty acid (FA) determination in 
platelet membranes, the lipid components, triglycerides, 
phospholipids and cholesteryl esters were first separated 
by two-dimensional thin layer chromatography. FAs in 
phospholipids were then analyzed by gas chromatography 
(Agilent, GC system, 6890 series; 6890A) [5]. During the 
LPS challenge blood was sampled in all subjects every 
30-60 min over the 8-h protocol to determine hormone 
levels (cortisol, ACTH, catecholamines), inftammatory 
markers (TNF-a, hsCRP), glucose, lactate, free FA and 
triglyceride plasma levels. Blood samples were collected 
into heparinized tubes and centrifuged (3,000/min for 10 
min at 4 °C) to separate plasma. Plasma was stored at - 20 
or -80°C depending on the matrix until analysis. Cortisol 
(kit from Diagnostic Products Corporation, Los Angeles, 
CA) was determined by radioimmunoassay. ACTH was 
determined by chemiluminescence assay (Nichols Insti-
tute Diagnostics, San Juan Capistrano, CA) (reference 
range 10-60 ng/1). Plasma catecholamines were deter-
mined by HPLC with electrochemical detection. 
ELISA in streptavidin-coated microtiter plates (Roche, 
Mannheim, Germany) was used for in vitro determination 
of TNF-ix. High sensitivity C-reactive protein (hsCRP) 
was measured by turbidimetry on a Hitachi 917 (Roche) 
and determined only at TO and at the end of the trial. 
Plasma glucose and lactate concentrations were mea-
sured enzymatically using a Yellow Spring Instrument 
YSI 2300 STAT PLUS (Yellow Spring, OH). Plasma free 
FA concentrations were measured with a colorimetric 
method using a kit from Wako (Neuss, Germany). 
Enzymatic determination of triglycerides in plasma was 
performed with a TG PAP 150 kit (BioMérieux, Lyon, 
France). 
Indirect calorimetry was performed continuously 
during the whole study (Datex, Deltatrac2, Helsinki, 
Finland). Respiratory gases were collected with a canopy 
to determine resting energy expenditure (REE) and net 
substrate oxidation. REE was calculated using the equa-
tion of Livesey and Elia [6]. 
Statistical analysis data are presented as mean ± SD. 
Areas under the curve (AUC) calculated using the trap-
ezoidal method were ûsed to compare the overall effect 
of FO between groups. The effect of time was explored 
by means of two-factor repeated measures ANOV A and 
n-3 PUFA dose (group = dose, group x time =inter-
vention). Post hoc comparisons were carried out by 
Dunnett's (effect of time versus baseline in each group) 
or Scheffe's test (between group comparisons at the same 
time point). Membrane incorporation changes and AUC 
were analyzed by non-parametric tests (Kruskal-Wallis). 
The statistical package was: JMP® Version 5.1., SAS 
Institute Inc., Cary, NC. Significance was considered at 
p:::: 0.05. 
Results 
The 23 subjects were aged 26.8 ± 3.2 years with a mean 
body mass index (BMI) of 22.5 ± 2.1 kg/m2• Demo-
graphic variables were similar between the groups. 
Platelet membrane incorporation 
EPA incorporation in platelet phospholipids was observed 
in all FO groups and was significantly higher in the group 
receiving the largest FO dose (day 1, 0.5 g/kg) compared 
with the two other groups (p < 0.018) (Table 1). DHA 
was also incorporated in platelet membranes, but the 
changes were not significant. 
Systemic effects of LPS 
Significant increases in heart rate ( +52% p < 0.0001) and 
cardiac output ( +40%, p < 0.0001) peaking at 1240 after 
LPS were observed in all subjects, while systolic, dia-
stolic, mean blood pressure and Sp02 did not change 
significantly. REE variability was substantial and did not 
reach steady state in the varions parts of the study pre-
cluding statistical analysis because of marked shivering 
(data not shown). Body temperature increased signifi-
cantly in all groups after LPS (Fig. 1). All subjects 
complained of transient headache, nausea and muscle 
pain. They were all discharged home symptom free, with 
no medication. 
Metabolism, cytoldnes and hormones 
There were modest changes in plasma glucose and lactate 
concentrations along the study from baseline, but these 
were not significant. 
LPS induced significant increases in plasma TNF-ix, 
norepinephrine, epinephrine and ACTH levels in all 
groups (Table 2). Figure 2 shows that FO attenuated 
several aspects of this response, with significant blunting 
Table 1 EP A and DHA in platelet phospholipids before and after FO infusion (TO) 
Group EP A (% molar) DHA (% molar) 
Before FO TO Change Before FO TO Change 
Day -1, 0.5 g/kg 0.41 ± 0.29 1.2 ± 0.15# +0.79## 2.23 ± 0.40 2.61 ± 0.37 +0.38 
Day -1, 0.2 g/kg 0.32 ± 0.12 0.68 ± 0.16** +0.36 1.97 ± 0.33 2.13 ± 0.55 +0.16 
Day 0, 0.2 g/kg 0.27 ± 0.25 0.67 ± 0.28* +0.40 2.49 ± 0.38 2.90 ± 0.61 +0.41 
The incorporations of the previous trial delivering 2 x 0.5 g/kg FO Statistically significant within-group changes by two-way ANOV A 
were higher (EPA +1.4, DHA +0.8% molar) [4] are indicated as* p = 0.05, ** p = 0.01, # p < 0.001. Difference 
between groups ## p = 0.018 
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Fig. 1 Temperature over time in the three groups after LPS 
injection: the increase was significantly blunted in all FO groups 
(p = 0.0002) compared with the contrai group (dotted line) of 
Pluess et al. (4] 
of the overall response of plasma TNF-o: by AUC 
(p < 0.0001) in the day -1, 0.2 g/kg and day-0, 0.2 g/kg 
groups compared to the day -1, 0.5 g/kg group. 
The AUC of ACTH and the peak levels after LPS 
were similarly lower in the day -1, 0.2 g/kg and day-0, 
0.2 g/kg groups compared to the day -1, 0.5 g/kg group 
(Fig. 2). Plasma norepinephrine did not differ among the 
three groups (Table 1). The increase in plasma epineph-
rine AUC was blunted significantly only in the day -1, 
0.2 g/kg group. Baseline hsCRP concentrations were 
modestly higher in the day -1, 0.5 g/kg group (ns: 
p = 0.14) and increased significantly only in the day -1, 
0.2 g/kg group (mg/l), remaining a trend in both other 
groups. 
Discussion 
In the present study, we tested the effects of three dif-
ferent decreasing regimens of intravenous FO on the cell 
membrane phospholipid composition and on the physio-
logical response to LPS. The data were further compared 
with those of our previous study, which was carried out 
with the same design and which included a control group 
[4]. The aim was to reduce both infusion time and the fat 
load, while keeping the blunting effects of FO observed in 
the first trial. We found that one or two 0.2-g/kg doses of 
FO, administered within the 24 h before LPS challenge, 
significantly inftuenced both membrane EPA content and 
important aspects of the response to LPS. 
Table 2 Evolution of the plasma TNF-o:, hormone concentrations and hsCRP after the LPS challenge 
TO T60 Tl20 T240 
TNF-o: ( <30 pg/ml) 
Day -1, 0.5 g/kg (n = 8) 9.4 ± 7.3 129.5 ± 69.8 383.6 ± 155.5 91.0 ± 20.0 
Day -1, 0.2 g/kg (n = 6) 6.9 ± 5.7 28.0 ± 8.8** 111.4 ± 25.7* 46.4 ± 9.9* 
Day 0, 0.2 g/kg (n = 7) 21.2 ± 4.1 36.7 ± 6.5** 121.2 ± 48.8* 62.0 ± 15.0 
TO Tl20 T240 T360 
Norepinephrine (reference range 0.47-2.94 nM/l) 
Day -1, 0.5 g/kg 2.57 ± 0.84 3.86 ± 1.14 1.75 ± 0.59 1.44 ± 0.39 
Day -1, 0.2 g/kg 2.13 ± 0.37 4.02 ± 1.45 2.01 ± 0.32 1.61 ± 0.29 
Day 0, 0.2 g/kg 1.97 ± 0.21 1.93 ± 0.32 1.91 ± 0.41 1.46 ± 0.15 
Epinephrine (reference range 0.02-0.44 nM/l) 
Day -1, 0.5 g/kg 0.35 ± 0.08 0.34 ± 0.02 0.36 ± 0.07 0.31 ± 0.05 
Day -1, 0.2 g/kg 0.14 ± 0.02 0.20 ± 0.04* 0.21 ± 0.03* 0.18 ± 0.03 
Day 0, 0.2 g/kg 0.19 ± 0.03 0.24 ± 0.05 0.31 ± 0.09 0.20 ± 0.05 
ACTH (reference range 10-60 ng/l) 
Day -1, 0.5 g/kg 30.9 ± 7.3 129.8 ± 43.9 109.4 ± 40.1 20.4 ± 3.9 
Day -1, 0.2 g/kg 6.2 ± 1.3*** 22.7 ± 3.9*** 21.8 ± 6.5** 3.0 ± 0.0** 
Day 0, 0.2 g/kg 3.6 ± 0.6*** 16.9 ± 8.4*** 33.4 ± 21.3** 6.3 ± 2.3** 
Cortisol (reference range 170-630 ng/l) 
Day -1, 0.5 g/kg 226 ± 51 411±123 458 ± 158 204 ± 96 
Day -1, 0.2 g/kg 297 ± 55 420 ± 95 490 ± 125 215 ± 80 
Day 0, 0.2 g/kg 195 ± 81 392 ± 145 515 ± 161 320 ± 235 
hsCRP (reference range <0.11 mg/l) 
Day -1, 0.5 g/kg 1.52 ± 2.83 2.81 ± 3.53 
Day -1, 0.2 g/kg 0.37 ± 0.12 0.57 ± 0.16* 
Day 0, 0.2 g/kg 0.74 ± 0.35 0.81 ± 0.34 
Statistics: Ail the hormone concentration changes over time were highly significant by two-way ANOV A, whereas the hsCRP change was 
significant only in the day -1, 0.5 g/kg group. Post hoc tests between groups, * p = 0.05, ** p = 0.01, *** p < 0.001 
Membrane incorporation of FO 
Fatty acids are incorporated into cell membrane phos-
pholipids and play key roles in the physico-chemical 
and functional characteristics of the cell membranes. 
This in turn modifies important cell properties, including 
regulation of the inflammatory response by modulating 
ecosanoid synthesis and down-regulating cell signaling 
and gene expression. The dietary F As determine in part 
the composition of membrane phospholipids [7]. Several 
important membrane characteristics are influenced by 
their fatty acid composition, as shown by experiments 
analyzing the effects of various FAs in murine macro-
phage cultures [8]; incorporation of saturated FA into 
macrophage membranes decreases their ability to 
phagocytize and to adherence to surfaces, while the 
phagocytic rates increase with an increasing degree of 
unsaturation. This is caused by the changes in mem-
brane structure and fluidity, the latter being increased by 
n-3 and reduced by n-6 PUFAs [9] compared with 
saturated fatty acids [8], influencing multiple pathways 
[10]. 
In this study, we observed that a single intravenous 
infusion of FO significantly increased EP A content in 
cell membranes. We observed a direct relation between 
the dose of FO and the platelet membrane incorpora-
tion: the lowest incorporations were observed in the 
two groups receiving 0.2 g/kg, while the highest uptake 
of EPA (two times higher) was found in the group 
receiving the largest FO dose (day -1, 0.5 g/kg; 
p < 0.0001). Furthermore, the EPA incorporation was 
higher in our previous study using two doses of 
0.5 g/kg FO, being 3.5 higher than in the groups 
receiving the lowest dose of the actual study. Such a 
finding suggests a direct dose effect. 
The n-3 PUFA incorporation after oral FO supple-
ments is a rather slow process. In healthy subjects 
receiving 6-9 g FO/day for 12 months, the incorporation 
half-life of EPA in serum cholesteryl esters was calcu-
lated to be 4.8 days, while a plateau was reached after 
4-8 weeks [7]. Recent data, including ours, show that the 
intravenous route strongly accelerates the incorporation 
into human cell membranes [4, 11]. In rats the bolus 
administration of a novel MCT-FO solution achieves 
incorporation of n-3 PUFAs into cell membranes after 
only 60 min [12]. The data of the present study confirm 
these preliminary data and report combined pharmaco-
logical and biological data. 
Modulation of the physiological response to LPS 
Several nutrients have been shown to modulate acute 
inflammation, such as FO, antioxidant micronutrients and 
glutamine. A large body of literature shows that FO 
downregulates the inflammatory processes by complex 
mechanisms including a decreased production of proin-
flammatory eicosanoid mediators (prostaglandins, 
leukotrienes, thromboxanes), increased production of 
DHA-derived resolvin Dl and protectin Dl, which 
attenuate neutrophil migration and attenuate NF-1çB 
activation and tissue damage in several disease models 
[13], regulation of cell signaling of pathways involved in 
immune responses and regulation of gene expression 
involved in inflammation (transcription factors PPARs 
and SREBPs) [9]. 
Experimental studies show that FO may influence the 
response to LPS: FO increases survival in guinea pigs 
submitted to lethal doses of LPS [14], improves 
splanchnic and vital organ hemodynamics, and reduces 
bacterial translocation [15]. This is also observed in 
critically i1l patients with acute inflammafory conditions 
such as ARDS sepsis and surgery receiving FO with 
parenteral nutrition [13]. 
In two previous studies in healthy subjects, FO was 
found to reduce fever, as well as the neuro-endocrine and 
inflammatory responses to LPS after 2-3 week of oral 
supplementation, respectively [16], or much faster with 
two large intravenous 0.5 g/kg FO doses [4]. In the 
present study, lower doses or even a single dose achieved 
similar changes. Interestingly, the blunting of the LPS 
effects differed with the dose and the timing of admin-
istration, and was not directly proportional to the total FO 
dose. Fever was attenuated in ail groups compared to the 
previous trial's control group (Fig. 1). TNF-o: response 
was significantly blunted only in the two groups with the 
lowest FO dose. The hypothalamo-pituitary adrenal 
responses were blunted in ail groups compared to the 
control group of the previous trial [4]. Blunting of the 
ACTH response was stronger in the 0.2 g/kg FO groups 
compared to the 0.5 g/kg group (p = 0.0019). In the low 
FO doses groups, the responses were not as clear eut for 
the sympato-adrenal responses ( epinephrine and 
norepinephrine ). 
Dose effect 
The study design, with consecutive trials, allowed 
describing the relationship between different doses of FO 
and biological responses. A direct effect of increasing 
doses of FO was observed with membrane EPA incor-
poration, completing the results of our previous study [ 4], 
suggesting a mass effect. Table 1 mentions the previous 
trial's higher incorporation after the double 0.5-g/kg dose. 
Such a dose pattern was not observed with DHA due to 
substantial inter-individual variability and the limited 
power of the study. 
The effect of FO on the response to LPS is complex. 
The effect on fever was not influenced by the dose: the 
blunting appears similar to that previously observed 
(Fig. 1). Surprisingly, the suppressive effect on TNF-o: 
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Fig. 2 Areas under the curve (AUC) of TNF-o: and ACTH after 
LPS infusion in the three groups: the strongest blunting was 
observed with the two lowest FO doses. The data from the previous 
trial are indicated in dotted bars (Pluess et al. [ 4]) 
and ACTH was significantly more pronounced in the two 
low-dose groups (0.2 g/kg) compared with the single or 
double 0.5-g/kg doses of the previous trial (Fig. 2). We 
have no clear explanation for this observation: timing, 
dose of FO, membrane incorporation and genetic factors 
seem to be the main causative factors. Fat emulsion 
composition is another possible cause. Various types of 
phospholipids, including phospholipids contained in any 
parenteral nutrition fat emulsion, strongly inhibit LPS-
induced cytokine release by complex mechanisms [17], 
including the direct binding of LPS. Even if the present 
protocol, in absence of data, does not allow to reach 
conclusions about direct LPS inhibition by fat emulsion, 
such a mechanism is likely in the subjects receiving FO 
immediately before LPS (day 0, 0.2 g/kg), as suggested 
by the strongest blunting of LPS response in this group. 
On the other hand, we have no clear explanation for the 
large ACTH and TNF-o: blunting observed in the day -1, 
0.2 g/kg group in which FO was infused 24 h before the 
LPS challenge. 
Limitations 
The study has limitations. The number of subjects per 
group was low, reducing the power of the statistical 
analysis. The biological effects of FO have substantial 
inter-individual variability with a potential for outliers 
related to factors including genetics: this might be 
amplified by the small numbers, although the data do not 
show real outliers. 
The limited power probably explains why the DHA 
membrane incorporation was not significant, contrasting 
with that of EPA, which had greater changes with a 
lower variability. AUCs were calculated for every 
variable, which is an appropriate method for a kinetic 
study with the advantage of reducing the negative 
impact of the small numbers with repeated determina-
tions. We determined membrane FA composition only 
in platelets and not in other immune cells responsible 
for the inftammatory response. A recent study per-
formed in healthy volunteers receiving intravenous FO 
showed similar incorporation dynamics in platelets, 
monocytes and erythrocytes [11], although with differ-
ent rates of incorporation. This suggests that monocyte 
membranes in our healthy volunteers were also inftu-
enced by the FO infusion. Further, we did not assess 
thromboxanes and leukotrienes, important targets of FO 
administration, which limits the interpretation of our 
results. 
Finally, to limit LPS administration in numerous 
control groups, a highly disagreeable procedure that 
incurs laboratory costs, we proceeded by consecutive 
trials. Such a design is commonly used in pharmacolog-
ical studies to reduce the number of experiments. This 
trial was not designed to determine the lowest dose of 
intravenous FO achieving a blunting effect, only one that 
could be used in clinical settings. 
Conclusion 
Altogether the results show that a small dose of par-
enteral FO administered just before a LPS challenge 
produces a significant EPA membrane incorporation 
already 6 h after the injection and attenuates the phys-
iological response to LPS. This was also observed with 
a single 0.2-g/kg dose. These results open important 
perspectives in pre-conditioning of patients before 
interventions known to elicit strong inftammatory 
responses. 
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